Recent performance and business snapshot

ICU Medical (ICUI) has drawn fresh attention after recent trading, with the stock last closing at $139.83. Investors are weighing the company’s current valuation alongside its role in critical hospital infusion and vital care products.

While the share price slipped 1.53% over the last trading day, it has a 7 day share price return of 7.13% and a 30 day share price return of 12.15%, contrasting with a 3 year total shareholder return that is down 24.81%. This suggests short term momentum has picked up after a weaker multi year experience.

If ICU Medical has you looking more closely at healthcare, it could be a useful moment to scan a broader set of opportunities through our 39 healthcare AI stocks

With ICU Medical trading at $139.83 and both an indicated intrinsic value and analyst target sitting higher, the key question is straightforward: is the stock quietly undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 19.1% Undervalued

With ICU Medical last closing at $139.83 against a most followed fair value estimate of $172.86, the current price sits well below that narrative view.

The multiyear replacement cycle for ICU Medical's large installed base of infusion pumps is only now beginning, with refresh and value-capture opportunities expected to meaningfully contribute to revenue growth and recurring cash flows starting next year; positive forward-looking catalyst for both top-line and earnings.

Want to see what is baked into that fair value gap? The narrative leans on steady revenue expansion, wider profit margins, and a richer earnings profile over time.

Result: Fair Value of $172.86 (UNDERVALUED)

However, this depends on tariffs remaining manageable and regulatory scrutiny not escalating, since sustained cost pressure or delayed approvals could quickly weaken the current upside case.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another angle on valuation

The analyst narrative leans on earnings and cash flow, but the current P/E of 75.4x paints a very different picture. It sits well above the estimated fair ratio of 30.5x, the US Medical Equipment industry at 25.4x, and peers at 28.8x. This raises a clear question about valuation risk. If sentiment cools, could the market simply drift toward those lower multiples?

For a closer look at how earnings, cash flow, and multiples fit together, check the valuation breakdown in our See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this combination of potential upside and concern leaves you unsure, promptly review the underlying data and form your own judgment by weighing the 4 key rewards and 3 important warning signs.

Looking for more investment ideas?

If ICU Medical is on your radar, do not stop there. Broadening your watchlist now can help you spot opportunities before they feel obvious.

• Target potential mispricings by scanning for quality stocks that appear overlooked using the 47 high quality undervalued stocks.
• Strengthen your income focus by reviewing companies with reliable payouts highlighted in the 9 dividend fortresses.
• Prioritize resilience by searching for companies with robust finances in the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.